Search by Drug Name or NDC
NDC 72854-0263-40 MUCINEX INSTASOOTHE 5; 2 mg/1; mg/1 Details
MUCINEX INSTASOOTHE 5; 2 mg/1; mg/1
MUCINEX INSTASOOTHE is a ORAL LOZENGE in the HUMAN OTC DRUG category. It is labeled and distributed by RB Health (US) LLC. The primary component is DEXTROMETHORPHAN HYDROBROMIDE; HEXYLRESORCINOL.
Product Information
NDC | 72854-0263 |
---|---|
Product ID | 72854-263_8b2a3599-ea97-4eaf-bf5c-20eef840bda6 |
Associated GPIs | 88209902214720 |
GCN Sequence Number | 082552 |
GCN Sequence Number Description | dextromethorph/hexylresorcinol LOZENGE 5 MG-2 MG ORAL |
HIC3 | H6C |
HIC3 Description | ANTITUSSIVES, NON-OPIOID |
GCN | 50004 |
HICL Sequence Number | 047517 |
HICL Sequence Number Description | DEXTROMETHORPHAN HBR/HEXYLRESORCINOL |
Brand/Generic | Brand |
Proprietary Name | MUCINEX INSTASOOTHE |
Proprietary Name Suffix | SORE THROAT PLUS COUGH RELIEF |
Non-Proprietary Name | DEXTROMETHORPHAN HYDROBROMIDE and HEXYLRESORCINOL |
Product Type | HUMAN OTC DRUG |
Dosage Form | LOZENGE |
Route | ORAL |
Active Ingredient Strength | 5; 2 |
Active Ingredient Units | mg/1; mg/1 |
Substance Name | DEXTROMETHORPHAN HYDROBROMIDE; HEXYLRESORCINOL |
Labeler Name | RB Health (US) LLC |
Pharmaceutical Class | Sigma-1 Agonist [EPC], Sigma-1 Receptor Agonists [MoA], Uncompetitive N-methyl-D-aspartate Receptor Antagonist [EPC], Uncompetitive NMDA Receptor Antagonists [MoA] |
DEA Schedule | n/a |
Marketing Category | OTC MONOGRAPH NOT FINAL |
Application Number | part356 |
Listing Certified Through | 2024-12-31 |
Package
Package Images

NDC 72854-0263-40 (72854026340)
NDC Package Code | 72854-263-40 |
---|---|
Billing NDC | 72854026340 |
Package | 40 POUCH in 1 BAG (72854-263-40) / 1 LOZENGE in 1 POUCH |
Marketing Start Date | 2021-07-01 |
NDC Exclude Flag | N |
Pricing Information | |
Price Per Unit | 0.12311 |
Pricing Unit | EA |
Effective Date | 2024-02-21 |
NDC Description | MUCINEX INSTASOOTH COUGH 5-2 MG |
Pharmacy Type Indicator | C/I |
OTC | Y |
Explanation Code | 1, 6 |
Classification for Rate Setting | B |
As of Date | 2024-02-21 |
This pricing file, entitled the NADAC (National Average Drug Acquisition
Cost) files, provide
state Medicaid agencies with covered outpatient drug prices by averaging
survey invoice
prices from retail community pharmacies across the United States. These
pharmacies include
independent retail community pharmacies and chain pharmacies. The prices
are updated on a
weekly and monthly basis
Standard Product Labeling (SPL)/Prescribing Information SPL 8d670d91-9e22-45b9-b568-5b62c2133d32 Details
SPL UNCLASSIFIED SECTION
Uses
Warnings
Sore throat warning
If sore throat is severe, persists for more than 2 days, is accompanied or followed by fever, headache, rash, swelling, nausea, or vomiting, consult a doctor promptly.
Do not use
- if you are now taking a prescription monoamine oxidase inhibitor (MAOI) (certain drugs for depression, psychiatric, or emotional conditions, or Parkinson's disease), or for 2 weeks after stopping the MAOI drug. If you do not know if your prescription drug contains an MAOI, ask a doctor or pharmacist before taking this product.
- in children under 6 years of age
Ask a doctor before use if you have
- persistent or chronic cough such as occurs with smoking, asthma, or emphysema
- cough that occurs with too much phlegm (mucus)
Directions
dose as follows or as directed by a doctor or dentist
adults and children 12 years of age and older | take 2 lozenges (one immediately after the other) and allow each lozenge to dissolve slowly in the mouth; may be repeated every 4 hours as needed, not to exceed 12 lozenges in any 24-hour period |
children 6 to under 12 years of age | take 1 lozenge and allow product to dissolve slowly in the mouth; may be repeated every 4 hours as needed, not to exceed 6 lozenges in any 24-hour period |
children under 6 years of age | do not use |
Inactive ingredients
PRINCIPAL DISPLAY PANEL - 20 Drop Pouch Bag
INGREDIENTS AND APPEARANCE
MUCINEX INSTASOOTHE
SORE THROAT PLUS COUGH RELIEF
dextromethorphan hydrobromide and hexylresorcinol lozenge |
||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||
|
Labeler - RB Health (US) LLC (081049410) |
Revised: 6/2021
Document Id: 8b2a3599-ea97-4eaf-bf5c-20eef840bda6
Set id: 8d670d91-9e22-45b9-b568-5b62c2133d32
Version: 1
Effective Time: 20210617